Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
about
Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysisBest practice in the treatment of nonmuscle invasive bladder cancer.Association of smoking status with prognosis in bladder cancer: A meta-analysis.Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.Current strategies in the treatment of non-muscle-invasive bladder cancer.Follow-up procedures for non-muscle-invasive bladder cancer: an update.Urethral carcinoma in situ: recognition and management.The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis.Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063).Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.Conservative management and female gender are associated with increased cancer-specific death in patients with isolated primary urothelial carcinoma in situ.[Urine cytology - update 2013. A systematic review of recent literature].Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis.Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
P2860
Q26859123-428174B7-8443-491E-B42D-16DC9F33ECAEQ35688392-62085C23-BC3A-47F2-BADA-3EF4675E9396Q36207920-551C9FB2-FC69-4870-9EC0-236EA1DBDE76Q37813081-9693C731-7424-470B-8BA2-D3B7C7CE1ADAQ38048823-FEF50907-F210-4FFB-9B12-3A6D381D09D7Q38055500-434EF1F7-5276-4423-8ED6-FF68702279E3Q39013320-91D1C670-71C2-4ADC-97A5-445D7E70321DQ39634006-1BE7C9E5-3890-453E-9126-5B24C60E68FCQ40197490-9A27CE7B-D5D4-4964-A0F9-296A6F8BA98FQ42237719-224CAA62-1C74-4725-A770-169052DCD993Q44508630-7CCFF42F-9DD9-4BBC-B0A3-10CC3E752744Q45139625-A5D59C06-2E47-4CFF-8A89-6843AA80D813Q47262331-A07A5AFC-8916-41E2-BCB0-7E342AB1E1F1Q51820157-A585B8DF-E2F4-4042-8CB8-33C998B228EE
P2860
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@ast
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@en
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@nl
type
label
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@ast
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@en
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@nl
prefLabel
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@ast
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@en
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@nl
P2093
P2860
P50
P1476
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
@en
P2093
Angel M Cronin
Caroline J Savage
Daher C Chade
Guilherme Godoy
Harry W Herr
Shahrokh F Shariat
P2860
P356
10.1016/J.JURO.2010.03.032
P407
P577
2010-07-01T00:00:00Z